Press Releases

We’re Delivering the Promise of Healthier Lives.

CURE PHARMACEUTICAL 

Press Releases

We specialize in optimal formulations to achieve targeted release and exposure of medications.​

CURE Pharmaceutical to Present at the 9th Annual LD Micro Invitational

CURE Pharmaceutical to Present at the 9th Annual LD Micro Invitational

LOS ANGELES, May 30, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 9th Annual LD Micro Invitational on Wednesday, June 5th at 11:40 a.m. PT at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference will be held on June 4-5, 2019. […]

read more
CURE Pharmaceutical Secures Patent on Oral Thin Film Containing Bioactive Cannabinoid Molecules

CURE Pharmaceutical Secures Patent on Oral Thin Film Containing Bioactive Cannabinoid Molecules

OXNARD, Calif. – May 22, 2019 – CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the issuance of U.S. Patent No. 10,307,397, which covers the high load of bioactive cannabinoid molecules integrated into oral thin film dosage forms. The cannabinoids include cannabidiol (CBD) and tetrahydrocannabinol (THC). “Advances in drug delivery are […]

read more
CURE Pharmaceutical Closes Acquisition Of Privately-Held Chemistry Holdings Inc.

CURE Pharmaceutical Closes Acquisition Of Privately-Held Chemistry Holdings Inc.

Acquired Technology Expands Core CUREfilm™ Platform and Strengthens Balance Sheet OXNARD, Calif., May 14, 2019 (GLOBE NEWSWIRE) — Cure Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has closed on the previously announced acquisition of Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative […]

read more
Meroven LLC and CURE Pharmaceutical Enter Exclusive Marketing and Distribution Agreement for Spee-D for the USA

Meroven LLC and CURE Pharmaceutical Enter Exclusive Marketing and Distribution Agreement for Spee-D for the USA

CHICAGO – May 2, 2019 – Today, at the CPhI Conference, Meroven LLC announced a five-year agreement with CURE Pharmaceutical Corporation (OTCQB: CURR) to exclusively market and distribute Spee-D®, a weekly dose oral thin film Vitamin D3 in the USA. Under the terms of the agreement, Meroven LLC will be responsible for conducting all regulatory […]

read more
CURE Pharmaceutical Extends Closing Of Privately-Held Chemistry Holdings Inc. Acquisition to May 13

CURE Pharmaceutical Extends Closing Of Privately-Held Chemistry Holdings Inc. Acquisition to May 13

OXNARD, Calif., May 01, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has extended the close of the previously announced acquisition of Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”) to May 13, 2019. This merger transaction with Chemistry Holdings, a formulation technology company that […]

read more
CURE Pharmaceutical to Present at the Planet Microcap Showcase 2019

CURE Pharmaceutical to Present at the Planet Microcap Showcase 2019

CURE CEO to discuss expanded product pipeline and company’s continued execution into cannabinoid market. LAS VEGAS – April 30, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it will be presenting at the Planet MicroCap Showcase at 8:30 a.m. on Wednesday, May 1, 2019 and CEO Rob […]

read more

CURE Pharmaceutical Named “Innovative Business of the Year” By Oxnard Chamber of Commerce

OXNARD, Calif., April 26, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, has been named 2019’s Innovative Business of the Year by Oxnard Chamber of Commerce in recognition to the company’s innovative thinking for various programs, employing pioneering technology and a dedication to improving the health of […]

read more
Uptick Newswire Hosts CURE Pharmaceutical on The Stock Day Podcast to Discuss Major Milestones and 2019 Goals

Uptick Newswire Hosts CURE Pharmaceutical on The Stock Day Podcast to Discuss Major Milestones and 2019 Goals

PHOENIX, AZ / ACCESSWIRE / April 16, 2019 / Uptick Newswire Stock Day Podcast welcomed CURE Pharmaceutical (OTCQB: CURR) (”the Company”), a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CEO Rob Davidson joined Stock Day host Everett Jolly. To […]

read more
United Smart Cities and Cure Pharmaceutical Launch Global Healthcare Awareness Initiative

United Smart Cities and Cure Pharmaceutical Launch Global Healthcare Awareness Initiative

LOS ANGELES, April 9, 2019 —CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced a global healthcare awareness initiative with United Smart Cities for the purpose of educating, informing and providing the next generation healthcare solutions to the world’s 7.3 billion citizens.Recognizing escalating healthcare costs, CURE and United Smart Cities will […]

read more
CURE Pharmaceutical to Acquire Privately-Held Chemistry Holdings Inc., Expanding Its Technology Platform in Oral Drug Delivery

CURE Pharmaceutical to Acquire Privately-Held Chemistry Holdings Inc., Expanding Its Technology Platform in Oral Drug Delivery

** For FREQUENTLY ASKED QUESTIONS regarding this announcement, please click here to read FAQs ** OXNARD, Calif., April 1, 2019 – CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has agreed to acquire Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative delivery […]

read more

CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction

OXNARD, Calif., March 27, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has successfully completed a pre-IND (Investigational New Drug) review with the U.S. Food and Drug Administration (FDA). The FDA provided feedback supportive of CURE’s clinical development plans for its CUREfilm Blue, a soluble thin film […]

read more
CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant

CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant

OXNARD, Calif., March 12, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE to take […]

read more

National Healthcare Economics and Policy Expert Ruben Jose King-Shaw Jr. Joins CURE Pharmaceutical’s Board of Directors

The drug delivery leader taps former COO of U.S. Centers for Medicare & Medicaid Services to join growing Board   OXNARD, Calif., January 29, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced Ruben Jose King-Shaw Jr. has joined its Board of Directors. King-Shaw brings significant expertise in healthcare, […]

read more
CURE Pharmaceutical Appoints Chairman, Adds Member to Its Board of Directors

CURE Pharmaceutical Appoints Chairman, Adds Member to Its Board of Directors

The revolutionary drug delivery leader taps global finance strategist, William (Bill) Yuan, to head growing Board, which now includes prominent biotech investor, Dr. Gene Salkind OXNARD, Calif., January 15, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has appointed William (Bill) Yuan to Chairman of the Board […]

read more
CURE Pharmaceutical To Present at Benzinga Cannabis Capital Conference

CURE Pharmaceutical To Present at Benzinga Cannabis Capital Conference

LOS ANGELES, Jan. 09, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it will host an investor presentation at the Benzinga Cannabis Capital Conference at the Eden Roc Miami Beach Hotel in Miami on January 16, 2019 at 5pm.“This conference is the ideal kick-off to 2019, which […]

read more
CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals

CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals

OXNARD, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has secured a new registration with the Drug Enforcement Administration (DEA) as a manufacturer authorized to handle Schedule 1 controlled substances. With this license, CURE will develop and manufacture cannabinoid-based pharmaceutical products using its […]

read more
CURE Pharmaceutical Names Veteran Executive as Chief Financial Officer

CURE Pharmaceutical Names Veteran Executive as Chief Financial Officer

OXNARD, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has tapped Alex Katz to be the company’s Chief Financial Officer. Bringing his expertise in venture capital, Katz will oversee the company’s financial functions and investment relations.“Our company is approaching 2019 amidst exponential growth […]

read more
CURE Pharmaceutical to Present at CannX 2018 International Medical Cannabis Conference

CURE Pharmaceutical to Present at CannX 2018 International Medical Cannabis Conference

OXNARD, Calif. — October 10, 2018 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, will be presenting at this year’s CannX Conference on October 15 at 11:15 AM in Tel Aviv, Israel. CURE Pharmaceutical CEO Rob Davidson will present on “Maximizing and Understanding the Benefits of Proprietary Delivery Technologies for Increasing […]

read more
CURE Pharmaceutical Secures Patent for Oral Thin Film  Containing Bioactive Cannabinoid Molecules

CURE Pharmaceutical Secures Patent for Oral Thin Film Containing Bioactive Cannabinoid Molecules

LOS ANGELES, September 25, 2018 — CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, announced the allowance of an oral thin film patent (U.S. Patent No. 10092611), which covers the processing and integration of bioactive cannabinoid molecules into oral thin film dosage forms, such as CUREfilm™, the most advanced oral thin film on […]

read more
CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement

CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement

CURE grants cannabis leader rights to its proprietary drug delivery technology in markets around the world. LOS ANGELES, Sept. 05, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), (“CURE”), an innovative drug delivery and development company, today announced that it entered into a multi-year licensing agreement for the first time with a leading international cannabis company. […]

read more
Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.

Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.

OXNARD, Calif., July 11, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, announced today that it has signed a term sheet with Therapix Biosciences Ltd. (Nasdaq:TRPX), (“Therapix”), a specialty, clinical-stage pharmaceutical company developing cannabinoid-based treatments, to acquire the non-pain assets of Therapix, subject to the completion of the […]

read more